Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
Background. Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2015-11, Vol.61 (suppl_5), p.S586-S593 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S593 |
|---|---|
| container_issue | suppl_5 |
| container_start_page | S586 |
| container_title | Clinical infectious diseases |
| container_volume | 61 |
| creator | Chowdhury, Panchali Roy Meier, Christian Laraway, Hewad Tang, Yuxiao Hodgson, Abraham Sow, Samba O. Enwere, Godwin C. Plikaytis, Brian D. Kulkarni, Prasad S. Preziosi, Marie-Pierre Niedrig, Matthias |
| description | Background. Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in the EPI of countries in the African meningitis belt, and this study reports on the immunogenicity of the YF-17D vaccines in infants when administered concomitantly with measles vaccine and PsA-TT. Methods. Two clinical studies were conducted in Ghana and in Mali among infants who received PsA-TT concomitantly with measles and YF vaccines at 9 months of age. YF neutralizing antibody titers were measured using a microneutralization assay. Results. In both studies, the PsA-TT did not adversely affect the immune response to the concomitantly administered YF vaccine at the age of 9 months. The magnitude of the immune response was different between the 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana. Conclusions. Immunogenicity to YF vaccine is unaffected when coadministered with PsA-TT at 9 months of age. Further studies are warranted to better understand the determinants of the immune response to YF vaccine in infancy. Clinical Trials Registration. ISRCTN82484612 (PsA-TT-004); PACTR201110000328305 (PsA-TT-007). |
| doi_str_mv | 10.1093/cid/civ603 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4639505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26369162</jstor_id><sourcerecordid>26369162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-4cf1becec9e847cc87c5ee6c26b349da215803696251a2a485ea196a3091ee053</originalsourceid><addsrcrecordid>eNpdkc1rVDEUxYNY7Jcb90rAjQhP8_GSSTZCGWw70OLGKq5CJu--Tob3kprkjcx_34zTluoi3JD749yTexB6Q8knSjT_7HxXz0YS_gIdUcFnjRSavqx3IlTTKq4O0XHOa0IoVUS8QodMCsGlZkdovRjHKcRbCN75ssWxx79gGOIffA4bSPiHdc4HwPNou9EHnwsk6PBPX1b4GsJZn3xFsA_4EuxQVlu8CL0NJe-eLlY2WGxDh6_t4E_RQW-HDK8f6gm6Of_6fX7ZXH27WMzPrhrXMlWa1vV0CQ6cBtXOnFMzJwCkY3LJW91ZRoUi1bxkglpmWyXAUi0tJ5oCEMFP0Je97t20HKFzEEqyg7lLfrRpa6L15t9O8CtzGzemlVyLvwIfHgRS_D1BLmb02dWt2ABxyobOOJOEMM4q-v4_dB2nFOr3dpTUVGkhK_VxT7kUc07QP5mhxOwiNDVCs4-wwu-e239CHzOrwNs9sM4lpmf93TzJ-D0kfqJH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1736918956</pqid></control><display><type>article</type><title>Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Chowdhury, Panchali Roy ; Meier, Christian ; Laraway, Hewad ; Tang, Yuxiao ; Hodgson, Abraham ; Sow, Samba O. ; Enwere, Godwin C. ; Plikaytis, Brian D. ; Kulkarni, Prasad S. ; Preziosi, Marie-Pierre ; Niedrig, Matthias</creator><creatorcontrib>Chowdhury, Panchali Roy ; Meier, Christian ; Laraway, Hewad ; Tang, Yuxiao ; Hodgson, Abraham ; Sow, Samba O. ; Enwere, Godwin C. ; Plikaytis, Brian D. ; Kulkarni, Prasad S. ; Preziosi, Marie-Pierre ; Niedrig, Matthias</creatorcontrib><description>Background. Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in the EPI of countries in the African meningitis belt, and this study reports on the immunogenicity of the YF-17D vaccines in infants when administered concomitantly with measles vaccine and PsA-TT. Methods. Two clinical studies were conducted in Ghana and in Mali among infants who received PsA-TT concomitantly with measles and YF vaccines at 9 months of age. YF neutralizing antibody titers were measured using a microneutralization assay. Results. In both studies, the PsA-TT did not adversely affect the immune response to the concomitantly administered YF vaccine at the age of 9 months. The magnitude of the immune response was different between the 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana. Conclusions. Immunogenicity to YF vaccine is unaffected when coadministered with PsA-TT at 9 months of age. Further studies are warranted to better understand the determinants of the immune response to YF vaccine in infancy. Clinical Trials Registration. ISRCTN82484612 (PsA-TT-004); PACTR201110000328305 (PsA-TT-007).</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/civ603</identifier><identifier>PMID: 26553692</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; Babies ; Female ; Fever ; Ghana ; Healthy Volunteers ; Humans ; Immunization ; Immunization Schedule ; Immunology ; Infant ; Male ; Mali ; Measles Vaccine - administration & dosage ; Meningitis ; Meningococcal Vaccines - administration & dosage ; Neutralization Tests ; Public health ; SEROLOGIC AND SAFETY STUDIES OF A GROUP A MENINGOCOCCAL CONJUGATE VACCINE ; The Meningitis Vaccine Project: The Development, Licensure, , and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa ; Vaccines ; Yellow Fever Vaccine - administration & dosage ; Yellow Fever Vaccine - immunology</subject><ispartof>Clinical infectious diseases, 2015-11, Vol.61 (suppl_5), p.S586-S593</ispartof><rights>The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.</rights><rights>Copyright Oxford University Press, UK Nov 15, 2015</rights><rights>The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-4cf1becec9e847cc87c5ee6c26b349da215803696251a2a485ea196a3091ee053</citedby><cites>FETCH-LOGICAL-c428t-4cf1becec9e847cc87c5ee6c26b349da215803696251a2a485ea196a3091ee053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26369162$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26369162$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,27903,27904,57996,58229</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26553692$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chowdhury, Panchali Roy</creatorcontrib><creatorcontrib>Meier, Christian</creatorcontrib><creatorcontrib>Laraway, Hewad</creatorcontrib><creatorcontrib>Tang, Yuxiao</creatorcontrib><creatorcontrib>Hodgson, Abraham</creatorcontrib><creatorcontrib>Sow, Samba O.</creatorcontrib><creatorcontrib>Enwere, Godwin C.</creatorcontrib><creatorcontrib>Plikaytis, Brian D.</creatorcontrib><creatorcontrib>Kulkarni, Prasad S.</creatorcontrib><creatorcontrib>Preziosi, Marie-Pierre</creatorcontrib><creatorcontrib>Niedrig, Matthias</creatorcontrib><title>Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Background. Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in the EPI of countries in the African meningitis belt, and this study reports on the immunogenicity of the YF-17D vaccines in infants when administered concomitantly with measles vaccine and PsA-TT. Methods. Two clinical studies were conducted in Ghana and in Mali among infants who received PsA-TT concomitantly with measles and YF vaccines at 9 months of age. YF neutralizing antibody titers were measured using a microneutralization assay. Results. In both studies, the PsA-TT did not adversely affect the immune response to the concomitantly administered YF vaccine at the age of 9 months. The magnitude of the immune response was different between the 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana. Conclusions. Immunogenicity to YF vaccine is unaffected when coadministered with PsA-TT at 9 months of age. Further studies are warranted to better understand the determinants of the immune response to YF vaccine in infancy. Clinical Trials Registration. ISRCTN82484612 (PsA-TT-004); PACTR201110000328305 (PsA-TT-007).</description><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Babies</subject><subject>Female</subject><subject>Fever</subject><subject>Ghana</subject><subject>Healthy Volunteers</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Schedule</subject><subject>Immunology</subject><subject>Infant</subject><subject>Male</subject><subject>Mali</subject><subject>Measles Vaccine - administration & dosage</subject><subject>Meningitis</subject><subject>Meningococcal Vaccines - administration & dosage</subject><subject>Neutralization Tests</subject><subject>Public health</subject><subject>SEROLOGIC AND SAFETY STUDIES OF A GROUP A MENINGOCOCCAL CONJUGATE VACCINE</subject><subject>The Meningitis Vaccine Project: The Development, Licensure, , and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa</subject><subject>Vaccines</subject><subject>Yellow Fever Vaccine - administration & dosage</subject><subject>Yellow Fever Vaccine - immunology</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1rVDEUxYNY7Jcb90rAjQhP8_GSSTZCGWw70OLGKq5CJu--Tob3kprkjcx_34zTluoi3JD749yTexB6Q8knSjT_7HxXz0YS_gIdUcFnjRSavqx3IlTTKq4O0XHOa0IoVUS8QodMCsGlZkdovRjHKcRbCN75ssWxx79gGOIffA4bSPiHdc4HwPNou9EHnwsk6PBPX1b4GsJZn3xFsA_4EuxQVlu8CL0NJe-eLlY2WGxDh6_t4E_RQW-HDK8f6gm6Of_6fX7ZXH27WMzPrhrXMlWa1vV0CQ6cBtXOnFMzJwCkY3LJW91ZRoUi1bxkglpmWyXAUi0tJ5oCEMFP0Je97t20HKFzEEqyg7lLfrRpa6L15t9O8CtzGzemlVyLvwIfHgRS_D1BLmb02dWt2ABxyobOOJOEMM4q-v4_dB2nFOr3dpTUVGkhK_VxT7kUc07QP5mhxOwiNDVCs4-wwu-e239CHzOrwNs9sM4lpmf93TzJ-D0kfqJH</recordid><startdate>20151115</startdate><enddate>20151115</enddate><creator>Chowdhury, Panchali Roy</creator><creator>Meier, Christian</creator><creator>Laraway, Hewad</creator><creator>Tang, Yuxiao</creator><creator>Hodgson, Abraham</creator><creator>Sow, Samba O.</creator><creator>Enwere, Godwin C.</creator><creator>Plikaytis, Brian D.</creator><creator>Kulkarni, Prasad S.</creator><creator>Preziosi, Marie-Pierre</creator><creator>Niedrig, Matthias</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151115</creationdate><title>Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali</title><author>Chowdhury, Panchali Roy ; Meier, Christian ; Laraway, Hewad ; Tang, Yuxiao ; Hodgson, Abraham ; Sow, Samba O. ; Enwere, Godwin C. ; Plikaytis, Brian D. ; Kulkarni, Prasad S. ; Preziosi, Marie-Pierre ; Niedrig, Matthias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-4cf1becec9e847cc87c5ee6c26b349da215803696251a2a485ea196a3091ee053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Babies</topic><topic>Female</topic><topic>Fever</topic><topic>Ghana</topic><topic>Healthy Volunteers</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Schedule</topic><topic>Immunology</topic><topic>Infant</topic><topic>Male</topic><topic>Mali</topic><topic>Measles Vaccine - administration & dosage</topic><topic>Meningitis</topic><topic>Meningococcal Vaccines - administration & dosage</topic><topic>Neutralization Tests</topic><topic>Public health</topic><topic>SEROLOGIC AND SAFETY STUDIES OF A GROUP A MENINGOCOCCAL CONJUGATE VACCINE</topic><topic>The Meningitis Vaccine Project: The Development, Licensure, , and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa</topic><topic>Vaccines</topic><topic>Yellow Fever Vaccine - administration & dosage</topic><topic>Yellow Fever Vaccine - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chowdhury, Panchali Roy</creatorcontrib><creatorcontrib>Meier, Christian</creatorcontrib><creatorcontrib>Laraway, Hewad</creatorcontrib><creatorcontrib>Tang, Yuxiao</creatorcontrib><creatorcontrib>Hodgson, Abraham</creatorcontrib><creatorcontrib>Sow, Samba O.</creatorcontrib><creatorcontrib>Enwere, Godwin C.</creatorcontrib><creatorcontrib>Plikaytis, Brian D.</creatorcontrib><creatorcontrib>Kulkarni, Prasad S.</creatorcontrib><creatorcontrib>Preziosi, Marie-Pierre</creatorcontrib><creatorcontrib>Niedrig, Matthias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chowdhury, Panchali Roy</au><au>Meier, Christian</au><au>Laraway, Hewad</au><au>Tang, Yuxiao</au><au>Hodgson, Abraham</au><au>Sow, Samba O.</au><au>Enwere, Godwin C.</au><au>Plikaytis, Brian D.</au><au>Kulkarni, Prasad S.</au><au>Preziosi, Marie-Pierre</au><au>Niedrig, Matthias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2015-11-15</date><risdate>2015</risdate><volume>61</volume><issue>suppl_5</issue><spage>S586</spage><epage>S593</epage><pages>S586-S593</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Background. Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in the EPI of countries in the African meningitis belt, and this study reports on the immunogenicity of the YF-17D vaccines in infants when administered concomitantly with measles vaccine and PsA-TT. Methods. Two clinical studies were conducted in Ghana and in Mali among infants who received PsA-TT concomitantly with measles and YF vaccines at 9 months of age. YF neutralizing antibody titers were measured using a microneutralization assay. Results. In both studies, the PsA-TT did not adversely affect the immune response to the concomitantly administered YF vaccine at the age of 9 months. The magnitude of the immune response was different between the 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana. Conclusions. Immunogenicity to YF vaccine is unaffected when coadministered with PsA-TT at 9 months of age. Further studies are warranted to better understand the determinants of the immune response to YF vaccine in infancy. Clinical Trials Registration. ISRCTN82484612 (PsA-TT-004); PACTR201110000328305 (PsA-TT-007).</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>26553692</pmid><doi>10.1093/cid/civ603</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2015-11, Vol.61 (suppl_5), p.S586-S593 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4639505 |
| source | MEDLINE; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antibodies, Neutralizing - blood Antibodies, Viral - blood Babies Female Fever Ghana Healthy Volunteers Humans Immunization Immunization Schedule Immunology Infant Male Mali Measles Vaccine - administration & dosage Meningitis Meningococcal Vaccines - administration & dosage Neutralization Tests Public health SEROLOGIC AND SAFETY STUDIES OF A GROUP A MENINGOCOCCAL CONJUGATE VACCINE The Meningitis Vaccine Project: The Development, Licensure, , and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Vaccines Yellow Fever Vaccine - administration & dosage Yellow Fever Vaccine - immunology |
| title | Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T21%3A45%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20Yellow%20Fever%20Vaccine%20Coadministered%20With%20MenAfriVac%20in%20Healthy%20Infants%20in%20Ghana%20and%20Mali&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Chowdhury,%20Panchali%20Roy&rft.date=2015-11-15&rft.volume=61&rft.issue=suppl_5&rft.spage=S586&rft.epage=S593&rft.pages=S586-S593&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/civ603&rft_dat=%3Cjstor_pubme%3E26369162%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1736918956&rft_id=info:pmid/26553692&rft_jstor_id=26369162&rfr_iscdi=true |